DanCann Pharma Statistics
Total Valuation
DanCann Pharma has a market cap or net worth of SEK 17.89 million. The enterprise value is 18.97 million.
Market Cap | 17.89M |
Enterprise Value | 18.97M |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
DanCann Pharma has 1.54 billion shares outstanding. The number of shares has increased by 750.45% in one year.
Shares Outstanding | 1.54B |
Shares Change (YoY) | +750.45% |
Shares Change (QoQ) | +623.83% |
Owned by Insiders (%) | 0.34% |
Owned by Institutions (%) | 1.69% |
Float | 1.54B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.65 |
PB Ratio | 1.44 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.21 |
EV / Sales | 1.51 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.92 |
Financial Position
The company has a current ratio of 0.52
Current Ratio | 0.52 |
Quick Ratio | 0.45 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -25.73 |
Financial Efficiency
Return on equity (ROE) is -178.54% and return on invested capital (ROIC) is -106.08%.
Return on Equity (ROE) | -178.54% |
Return on Assets (ROA) | -80.87% |
Return on Capital (ROIC) | -106.08% |
Revenue Per Employee | 1.04M |
Profits Per Employee | -7.50M |
Employee Count | 12 |
Asset Turnover | 0.19 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.83% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -91.83% |
50-Day Moving Average | 0.01 |
200-Day Moving Average | 0.03 |
Relative Strength Index (RSI) | 43.37 |
Average Volume (20 Days) | 36,957,083 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DanCann Pharma had revenue of SEK 12.52 million and -90.01 million in losses. Loss per share was -0.13.
Revenue | 12.52M |
Gross Profit | -2.16M |
Operating Income | -85.57M |
Pretax Income | -88.90M |
Net Income | -90.01M |
EBITDA | -80.60M |
EBIT | -85.57M |
Loss Per Share | -0.13 |
Balance Sheet
Cash & Cash Equivalents | -1.08M |
Total Debt | n/a |
Net Cash | -1.08M |
Net Cash Per Share | -0.00 |
Equity (Book Value) | 9.66M |
Book Value Per Share | 0.01 |
Working Capital | -10.42M |
Cash Flow
In the last 12 months, operating cash flow was -20.65 million and capital expenditures -10,660, giving a free cash flow of -20.66 million.
Operating Cash Flow | -20.65M |
Capital Expenditures | -10,660 |
Free Cash Flow | -20.66M |
FCF Per Share | -0.01 |
Margins
Gross Margin | -17.27% |
Operating Margin | -683.60% |
Pretax Margin | -710.23% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -165.09% |
Dividends & Yields
DanCann Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -750.45% |
Shareholder Yield | -750.45% |
Earnings Yield | -1,102.17% |
FCF Yield | -115.48% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |